VAPO Overview

Merger Announcement: Vapotherm, Inc. has successfully completed its merger with a newly-formed entity funded by Perceptive Advisors, which includes the conversion of $83 million in debt to preferred equity and an additional $50 million investment from Perceptive.

Stock Delisting: Following the merger, Vapotherm's common stock trading on OTCQX has been suspended, and the company has requested delisting from the exchange.

Investigation of Companies: Halper Sadeh LLC is investigating Vapotherm, Strong Global Entertainment, Reneo Pharmaceuticals, and Squarespace for potential violations of federal securities laws and breaches of fiduciary duties related to their recent sales and mergers.

Shareholder Rights: The firm encourages shareholders from these companies to contact them for legal rights and options, offering representation on a contingent fee basis without upfront costs.

Investigation of Vapotherm Sale: Former Louisiana Attorney General Charles C. Foti, Jr. and Kahn Swick & Foti, LLC are investigating the proposed sale of Vapotherm, Inc. to Perceptive Advisors, which offers shareholders $2.18 per share, to assess if this amount is adequate or undervalues the company.

Legal Rights Inquiry: Shareholders who believe the sale undervalues Vapotherm can contact KSF for discussions about their legal rights regarding the transaction, with no obligation or cost involved.

Vapotherm Q2 2024 Earnings Report: Vapotherm reported a second quarter earnings per share of -$2.22 and revenue of $16.88 million.

Automated Earnings Coverage: InvestorPlace Earnings utilizes TradeSmith data to automate the reporting of quarterly earnings, providing quick insights into key financial figures without human intervention.

Financial Performance: Vapotherm, Inc. reported a 5.3% increase in net revenue for Q2 2024, totaling $16.9 million, driven by a significant rise in U.S. disposables revenue, which grew by 25.9% compared to the previous year. The company's gross margin improved to 49.1%, and its adjusted EBITDA loss decreased from $6.4 million in Q2 2023 to $2.9 million in Q2 2024.

Operational Highlights: The company noted increased adoption of its respiratory technology among COPD patients following positive study results presented at a recent congress. However, it faced challenges with international revenue, which declined by 15% due to reduced disposables sales in distributor markets.